Annexon, Inc (ANNX)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | PHARMACEUTICALS |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Douglas Love |
| Employees: | 60 |
| Web site: | annexonbio.com |
|
1400 SIERRA POINT PARKWAY, BLDG C, SUITE 200, BRISBANE, CA, 94005
(650)-822-5500
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain-baré syndrome. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Please log in first to see chart